南方科技大学知识苑(SUSTech KC): Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).

Title	Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
Author	Mai, Hai-Qiang ; Chen, Qiu-Yan ; Chen, Dong-Ping ; Hu, Chaosu ; Yang, Kunyu ; Wen, Jiyu ; Li, Jin-Gao ; Shi, Yingrui ; Jin, Feng ; Xu, Ruilian ; Pan, Jian-Ji ; Qu, Shenhong ; Li, Ping ; Hu, Chunhong ; Liu, Yi-Chun ; Jiang, Yi ; He, Xia ; Wang, Hung-Ming ; Lim, Darren Wan-Teck ; Xu, Rui-Hua
Publication Years	2023-06-01
ISSN	0732-183X
EISSN	1527-7755
Source Title	JOURNAL OF CLINICAL ONCOLOGY
Volume	41
Issue	16
Publication Place	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
Publisher	LIPPINCOTT WILLIAMS & WILKINS
SUSTech Authorship	Others
Language	English
URL	[Source Record]
Indexed By	SCI
WOS Research Area	Oncology
WOS Subject	Oncology
WOS Accession No	WOS:001053772003130
ESI Research Field	CLINICAL MEDICINE
Data Source	Web of Science
Citation statistics	Cited Times [WOS]:1
Document Type	Conference paper
Identifier	http://kc.sustech.edu.cn/handle/2SGJ60CL/571745
Department	Shenzhen People's Hospital
Affiliation	1.Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Carcinoma, Guangzhou, Peoples R China 2.Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China 3.Guangzhou Med Univ, Affiliated Canc Hosp, Guangzhou, Peoples R China 4.Fudan Univ, Ctr Canc, Shanghai, Peoples R China 5.Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China 6.Guangdong Med Univ, Affiliated Hosp, Zhanjiang, Peoples R China 7.Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China 8.Hunan Canc Hosp, Changsha, Peoples R China 9.Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China 10.Guizhou Med Univ, Doctoral Res Start Up Fund Project, Affiliated Hosp, Guiyang, Guizhou, Peoples R China 11.Jinan Univ, Secondary Clin Med Coll, Shenzhen Peoples Hosp, Jinan, Peoples R China 12.Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen, Peoples R China 13.Fujian Canc Hosp, Fuzhou, Peoples R China 14.Peoples Hosp Guangxi Zhuang Autonomous Reg, Nanning, Peoples R China 15.Sichuan Univ, West China Hosp, Chengdu, Peoples R China 16.Cent South Univ, Xiangya Hosp 2, Changsha, Peoples R China 17.Taichung Vet Gen Hosp, Dept Radiat Oncol, Taichung, Taiwan 18.Shantou Univ, Canc Hosp, Coll Med, Shantou, Peoples R China 19.Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China 20.Chang Gung Mem Hosp, Div Hematol Oncol, Dept Internal Med, Taoyuan, Taiwan 21.Natl Canc Ctr Singapore, Singapore, Singapore 22.Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Peoples R China
Recommended Citation GB/T 7714	Mai, Hai-Qiang,Chen, Qiu-Yan,Chen, Dong-Ping,et al. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).[C]. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA:LIPPINCOTT WILLIAMS & WILKINS,2023.

Files in This Item:
There are no files associated with this item.

If you have any objections to this item, please fill out the form below and the administrator will contact you as soon as possible.
Content:
Email：	*
Affiliation Sequential No:
Verification Code:	Refresh

Any comments and suggestions are welcomed.
Title:	*
Content:
Email：	*
Verification Code:	Refresh